BELMONT, Calif.--(BUSINESS WIRE)--LakePharma, Inc. the leading protein engineering CRO dedicated to providing integrated biologics discovery and development services, will present key data at the upcoming PEGS 2016 Protein Engineering Summit in the form of several case studies highlighting the challenges that arise from the multiple domain nature of fusion protein therapeutics. Specifically, Hua Tu, Ph.D., LakePharma’s Chairman and CEO, will share data for the design, engineering, bioanalytical characterization and manufacturability assessment of Fc fusions and bispecific antibodies.
Company scientists will also present a poster detailing a tandem mass spectrometry approach to proteomic sequencing that enables the accurate determination of an antibody’s primary sequence when the source hybridoma is unavailable. In addition to revealing the full sequence of an important antibody, their approach enabled the engineering of the antibody to improve its production by CHO cells, as well as its performance as a purification reagent.
Details on Presentation and Poster Sessions
Overcoming Multiple Domain Challenges of Fc Fusions and Fab Fusion
Speaker: Hua Tu, Chairman and CEO, LakePharma
Day: Tuesday April 26, 2016
Time: 3:05 - 3:35 pm ET
Track: Fusion Protein Therapeutics: Engineering Enzymes
Poster A63: Proteomic Sequencing and Resurrection of a Monoclonal
Authors: Natalie Castellana, Digital Proteomics; Kexin Huang and Hua Tu, LakePharma
Presentation: April 25 and 26
“As specialists in antibody discovery and protein engineering, our bi-coastal team is well positioned to offer pharmaceutical and biotechnology companies the most comprehensive continuum of services to enhance the quality and speed of their biologics discovery and development,” said Dr. Tu.
Celebration of Merger with Blue Sky BioServices
The company invites all PEGS Boston attendees to join the LakePharma team at a cocktail party celebrating LakePharma’s acquisition of Blue Sky BioServices on the evening of Tuesday April 26 from 4:30 to 6:30 pm at Jerry Remy’s Seaport location. For more details on this event, please visit either of our PEGS booths, #241 and #319.
“The joining of LakePharma and Blue Sky BioServices at the end of March has created the U.S. biotech and pharmaceutical industry’s largest CRO dedicated to biologics,” said Dr. Tu. “Together, our comprehensive capabilities in antibody development, protein expression and characterization, molecular biology, and protein analytics provide a full continuum of services for discovery and early stage biotherapeutic development. Moreover, with four facilities in the San Francisco Bay Area and Cambridge/Boston areas, we’re based right where our clients are -- in the nation’s greatest biotech hubs.”
LakePharma is a contract research organization (CRO) dedicated to serving the discovery research and protein engineering needs of companies engaged in the development of biotherapeutics. The company has assembled the United States’ most comprehensive suite of technologies and expertise to offer a large continuum of services for antibody and protein discovery and engineering, cell line creation, and protein analytics. Clients may access our services individually or as a fully integrated “soup to nuts” solution for all of their molecular biology, protein chemistry, cell line, assay, and production scale-up needs. Moreover, LakePharma provides superior client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal, Datasystems. For more information, please visit www.lakepharma.com.